PIERIS PHARMACEUTICALS, INC. (NASDAQ:PIRS) Files An 8-K Regulation FD Disclosure
Item 7.01: Regulation FD Disclosure.

Pieris Pharmaceuticals, Inc. (“Pieris”) announced today that it has dosed the first healthy subjects in its Phase I study of PRS-060, an inhaled Anticalin® protein targeting IL-4Ra. PRS-060 is being developed in partnership with AstraZeneca AB (“AstraZeneca”), who is funding the study, while Pieris’ wholly-owned affiliate, Pieris Australia Pty Ltd., is the study sponsor.

The dosing of PRS-060 in this Phase 1 study has triggered a $12.5 million milestone payment from AstraZeneca to Pieris.

The information set forth under this “Item 7.01. Regulation FD Disclosure,” shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

About PIERIS PHARMACEUTICALS, INC. (NASDAQ:PIRS)

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company’s second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.